

Charisma Y. Atkins, DrPH, MPH

Scientific and Clinical Engagement

Atlanta, GA | cyatkins@msn.com | [linkedin.com/in/charismaatkins](https://www.linkedin.com/in/charismaatkins)

Senior epidemiologist and public health scientist with 15+ years of technical and scientific expertise across multiple therapeutic areas, including infectious and chronic diseases, virology, immunology, oncology, endocrinology, and autoimmune-specific rheumatology. Public- and private-sector experience engaging HCPs, KOLs, and academic partners; translating complex clinical and scientific data to support research, clinical development, and evidence generation. Expertise in real-world evidence (RWE) generation aligned with FDA guidance, OIG compliance standards, and IRB submission. Deep knowledge of the clinical development process, clinical trial management, ICH guidelines, and REDCAP data entry. Proven ability to build professional relationships, capture medical and public health insights, and communicate emerging data and evidence-based recommendations to clinical and scientific audiences. Leadership experience in public health surveillance, outbreak investigations, case investigations, vaccine and intervention effectiveness, stakeholder engagement, and cross-functional collaboration with state health departments, clinical sites, academic centers, international organizations, and community partners. Published author of peer-reviewed research with international field experience supervising operations across seven countries.

EDUCATION

Doctor of Public Health (DrPH) — University of Georgia, Athens, GA

Master of Public Health (MPH), Epidemiology — Florida A&M University, Tallahassee, FL

Bachelor of Science, Biology Research — Florida A&M University, Tallahassee, FL

CORE COMPETENCIES

HCP & KOL Engagement | Medical Insights Capture | Scientific & Clinical Communication | Emerging Data & Pipeline Discussions | Patient Journey & Unmet Medical Need | Communicable, Chronic & Infectious Disease Epidemiology | Clinical Trials | Investigational Sites | IRB & GCP | Territory Planning & Stakeholder Mapping | HEOR & Market Access Collaboration | Adverse Event Reporting | OIG & Regulatory Compliance | RWE & Observational Research | Statistical Analysis (SAS, R, SQL) | Scientific Publication & Presentation | Data Collection & Analysis | Operational & Statistical Reports | Peer-Reviewed Publications, Manuscripts, Internal Reports & Policy Briefs | International Field Operations & Supervision

PROFESSIONAL EXPERIENCE

Bridged Impact Consulting

Health Advisor & Epidemiology Consultant

Aug 2025 – Present

- Engage HCPs, including physicians, nurses, scientists, and other healthcare professionals, through in-person and virtual scientific exchange sessions on Lupus, Oncology, Chronic Kidney Disease, and women's health.
- Provide technical and scientific expertise on communicable and chronic disease epidemiology to health organizations, academic medical centers and community organizations.
- Build and maintain professional relationships with KOLs, advocacy organizations, and academic partners, serving as a Lupus Ambassador and Panelist at scientific forums and community events.
- Monitor emerging biologic and autoimmune therapies, including chemotherapy, CAR T-cell immunotherapy, and radiation, to support scientific exchange and emerging discussions with KOLs, HCP, and patients.
- Develop formal scientific presentations on the impact of Lupus treatment therapies, including CAR T-cell therapy and other biologics, on minority and underserved populations.
- Conducted emerging data discussions with referring HCPs and clinical stakeholders, translating complex findings into balanced, evidence-based scientific information in alignment with OIG compliance standards.
- Capture medical insights through patient interviews, educational forums, and community engagements, identifying recruitment, engagement, and retention barriers in the patient journey and areas of unmet medical need across autoimmune and chronic disease populations.
- Respond to unsolicited medical inquiries and capture/report adverse events in compliance with applicable standards.
- Partner with academic centers and centers of excellence to support disease education and evidence-based engagement.
- Assess feasibility of conducting clinical trials at investigational sites, including applicability of study data, patient population availability, and delivery of study results.
- Develop scientifically accurate patient and HCP education materials, ensuring content adheres to regulatory and ethical communication standards.

Centers for Disease Control & Prevention
Epidemiologist, Office of Women's Health

Feb 2021 – Aug 2025

- Represented CDC at inter-agency meetings and scientific forums; served as the medical and scientific resource to internal and external stakeholders on Lupus, Cervical Cancer, and gynecologic oncology throughout the product development lifecycle.
- Led design and execution of RWE and epidemiologic studies aligned with FDA real-world evidence guidance, developing study protocols, statistical analysis plans, research dissemination plans, and research concepts to support clinical strategy and regulatory engagement.
- Captured health insights from cross-functional discussions, literature, and surveillance data; translated findings into actionable guidance informing clinical trial design, endpoint selection, and disease surveillance strategy.
- Identified key stakeholders across the patient journey and disease space; mapped engagement priorities and drove strategic partnerships with federal agencies, academic centers, and advocacy organizations.
- Collaborated cross-functionally with clinical and health economic & outcomes research (HEOR), analytics, and programs to advance evidence-based practice and align scientific outputs with public health strategy.
- Managed and participated in investigations with national impact, overseeing Lupus and Cervical Cancer research portfolios across registries, investigational sites, and surveillance study designs.

Health Scientist, Division of Diabetes Translation

Jul 2016 – Feb 2021

- Led two end-to-end epidemiologic studies; provided clinical trial support across design, protocol development, and dissemination phases, working cross-functionally with research and program operations.
- Engaged referring HCPs and scientific partners at national conferences (ADA, APHA, CSTE) through oral presentations and non-promotional scientific exchange on Diabetes intervention effectiveness and emerging evidence.
- Captured health insights through structured interviews, literature reviews, and qualitative research by identifying screening, recruitment, and engagement barriers in the patient journey and areas of unmet need across high-risk Diabetes populations.
- Maintained in-depth knowledge of the endocrinology therapeutic landscape, monitoring regulatory guidance and emerging clinical evidence to serve as a scientific resource to program partners.
- Collaborated with investigational sites and matrixed research, analytical, and regulatory teams, contributing to relevant analyses supporting evidence-based program and policy decisions.
- Applied ML-enhanced methods (DistillerSR) to boost evidence-generation efficiency by 10–15%.

Lockheed Martin Corporation

Health Outcomes Researcher, Health Economics & Modeling Unit

Oct 2007 – Jul 2016

- Engaged pharmaceutical manufacturers, international health partners, and NGO advisory committees as a scientific resource on vaccine effectiveness, disease burden, and intervention strategy throughout the product lifecycle.
- Traveled internationally to supervise field operations and deliver technical assistance training across 7 LMIC countries, supporting global disease detection site operations.
- Provided public health emergency and clinical trial support, including review of investigator-initiated study proposals and SOP development aligned with GCP and regulatory guidance.
- Co-authored four peer-reviewed publications and MMWR reports; presented at national and international scientific meetings on epidemiologic methods, intervention effectiveness, and modeling outcomes.

TECHNICAL SKILLS & CERTIFICATIONS

Oncology Tumors | Health Economic Outcomes (HEOR) | CITI Certified | Good Clinical Practice (GCP) | IRB Protocols | FDA RWE Guidance | OIG Compliance | Scientific Writing & Publications | SAS | R | SQL | SPSS | Power BI | REDCap | Surveillance Systems (BRFSS, NHANES, HCUP) | Real-World Data (Claims, EHR, Registry) | ICD-10 / CPT / NDC Coding | AI-Enabled Tools (ChatGPT, Claude AI, Gemini, DistillerSR) | HIPAA

SELECT PUBLICATIONS & PRESENTATIONS

- Atkins CY (2023). [First Author] Evaluation of SDOH impact on COVID outcomes among low-income minority females (18–64). University of Georgia.
- Atkins CY, et al. (2011). Antiviral drugs and 2009 H1N1 hospitalizations. *Emerg Infect Dis* 17:1591–1598.
- Oral & International Presenter: APHA, American Diabetes Association, CSTE, and Science Forums.
- International Presenter & Field Supervisor: Global disease detection sites across 7 countries — epidemiologic methods, disease surveillance, and health economic modeling.